Varicella zoster virus reactivation reported with isatuximab use

Cumulative Incidence and Relative Risk of Infection in Multiple Myeloma Patients Treated with anti-CD38 Monoclonal Antibody-Based Regimens: A Systematic Review and Meta-Analysis

(2022) Stephanos Vassilopoulos et al.   Open Forum Infectious Diseases

Epidemiology and Risks of Infections in Patients With Multiple Myeloma Managed With New Generation Therapies

(2021) Chhay Lim et al.   Clinical Lymphoma Myeloma & Leukemia

Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

(2021) Philippe Moreau et al.   LANCET

Roles of CD38 in the Immune Response to Infection

(2020) Estibaliz Glaría et al.   Cells

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

(2019) Michel Attal et al.   LANCET

Prevention of viral infections in patients with multiple myeloma: the role of antiviral prophylaxis and immunization

(2015) Benjamin W Teh et al.   Expert Review of Anti-Infective Therapy